Loading clinical trials...
Loading clinical trials...
Torch: A Phase II Study to Determine the Safety and Efficacy of the Dual mTORC Inhibitor AZD2014 and to Investigate Additional Toxicities in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Conditions
Interventions
AZD 2014
Rituximab
Locations
9
United Kingdom
Aberdeen Royal Infirmary
Aberdeen, United Kingdom
Royal Liverpool University Hospital
Liverpool, United Kingdom
University College London Hospitals
London, United Kingdom
Guys Hospital
London, United Kingdom
The Christie NHS Foundation Trust
Manchester, United Kingdom
Norfolk & Norwich University Hospitals NHS Foundation Trust
Norwich, United Kingdom
Start Date
October 1, 2015
Primary Completion Date
September 7, 2017
Completion Date
February 6, 2020
Last Updated
November 5, 2020
NCT05139017
NCT01804686
NCT05755087
NCT04739813
NCT06785818
NCT06043011
Lead Sponsor
University of Birmingham
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions